title: p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.
abstract: p16, a nuclear protein encoded by the p16(INK4a) gene, is a regulator of cell-cycle regulation. Previous studies have shown that expression of p16 in tissue biopsies of patients with ductal carcinoma in situ (DCIS) is associated with increased risk of breast cancer, particularly when considered in combination with other markers such as Ki-67 and COX-2. Here, we evaluated how expression of p16 in breast tissue biopsies of women with atypical hyperplasia (AH), a putative precursor lesion to DCIS, is associated with subsequent development of cancer. p16 expression was assessed by immunohistochemistry in archival sections from 233 women with AH diagnosed at the Mayo Clinic. p16 expression in the atypical lesions was scored by percentage of positive cells and intensity of staining. We also studied coexpression of p16, with Ki-67 and COX-2, biomarkers of progression in AH. Risk factor and follow-up data were obtained via study questionnaire and medical records. Forty-seven patients (20%) developed breast cancer with a median follow-up of 14.5 years. Staining of p16 was increased in older patients relative to younger patients (P = 0.0025). Although risk of developing breast cancer was not associated with increased p16 expression, joint overexpression of Ki-67 and COX-2 was found to convey stronger risk of breast cancer in the first 10 years after diagnosis as compared with one negative marker (P < 0.01). However, the addition of p16 levels did not strengthen this association. p16 overexpression, either alone or in combination with COX-2 and Ki-67, does not significantly stratify breast cancer risk in women with AH.
authors.affiliation: Division of Biochemistry/Molecular Biology, Mayo Clinic in Jacksonville, Jacksonville, Florida 32224, USA. radisky.derek@mayo.edu
authors.forename: Derek C
authors.initials: DC
authors.lastname: Radisky
authors.forename: Marta
authors.initials: M
authors.lastname: Santisteban
authors.forename: Hal K
authors.initials: HK
authors.lastname: Berman
authors.forename: Mona L
authors.initials: ML
authors.lastname: Gauthier
authors.forename: Marlene H
authors.initials: MH
authors.lastname: Frost
authors.forename: Carol A
authors.initials: CA
authors.lastname: Reynolds
authors.forename: Robert A
authors.initials: RA
authors.lastname: Vierkant
authors.forename: V Shane
authors.initials: VS
authors.lastname: Pankratz
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Visscher
authors.forename: Thea D
authors.initials: TD
authors.lastname: Tlsty
authors.forename: Lynn C
authors.initials: LC
authors.lastname: Hartmann
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia / Q000378:metabolism* / Q000473:pathology; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000378:metabolism; D008875:Middle Aged; D011230:Precancerous Conditions / Q000378:metabolism* / Q000473:pathology; D012307:Risk Factors
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D019394:Ki-67 Antigen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human